Novo Nordisk A/S (Novo Nordisk A/S) Beginning Cash Position : $4,372 Mil (As of Dec. 2023)

View and export this data going back to 1981. Start your Free Trial

What is Novo Nordisk A/S Beginning Cash Position?

Novo Nordisk A/S's Beginning Cash Position for the quarter that ended in Dec. 2023 was $4,372 Mil.

Novo Nordisk A/S's quarterly Beginning Cash Position increased from Jun. 2023 ($2,173 Mil) to Sep. 2023 ($3,087 Mil) and increased from Sep. 2023 ($3,087 Mil) to Dec. 2023 ($4,372 Mil).

Novo Nordisk A/S's annual Beginning Cash Position declined from Dec. 2021 ($1,858 Mil) to Dec. 2022 ($1,526 Mil) but then increased from Dec. 2022 ($1,526 Mil) to Dec. 2023 ($1,851 Mil).

Novo Nordisk A/S Beginning Cash Position Historical Data

The historical data trend for Novo Nordisk A/S's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Beginning Cash Position Chart

Novo Nordisk A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

2,324.74

2,520.03

1,857.77

1,526.29

1,851.26

Novo Nordisk A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Beginning Cash Position	Get a 7-Day Free Trial															3,974.71	1,820.00	2,173.49	3,087.43	4,372.18

Novo Nordisk A/S Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Novo Nordisk A/S Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk A/S (Novo Nordisk A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (NYSE:NVO) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

NONOF:USA NOVOB:Mexico NVO:Mexico NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany NOV:Germany NOVA:Germany NOV:Germany NOV:Germany NOVA:Germany N1VO34:Brazil NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, DK-2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.